BCAL Diagnostics (ASX:BDX) EV-to-EBITDA : -3.53 (As of May. 18, 2024)

BCAL Diagnostics EV-to-EBITDA Chart

Competitive Comparison of BCAL Diagnostics's EV-to-EBITDA

For the Diagnostics & Research subindustry, BCAL Diagnostics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BCAL Diagnostics's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's EV-to-EBITDA falls into.

BCAL Diagnostics EV-to-EBITDA Calculation

BCAL Diagnostics's EV-to-EBITDA for today is calculated as:

BCAL Diagnostics's current Enterprise Value is A$22.98 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BCAL Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was A$-6.50 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics  (ASX:BDX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

BCAL Diagnostics's PE Ratio for today is calculated as:

BCAL Diagnostics's share price for today is A$0.105.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BCAL Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.022.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

BCAL Diagnostics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description